BACKGROUND: Retinoic acids, a group of natural and synthetic vitamin A derivatives, have potent anti-proliferative, anti-inflammatory and anti-fibrotic properties. We investigated the therapeutic effect of all-trans-retinoic acid (ATRA) on unilateral ureteral obstruction (UUO) model mice. METHODS: First, to evaluate the prophylactic effect, we administered 0.5 mg of ATRA for 3 days before UUO (UUO ATRA). Then, to evaluate the therapeutic effects, we administered 0.5 mg of ATRA 3 days after UUO (Day 3 ATRA). We compared the histological changes and immunostaining of macrophages, α-smooth muscle actin (α-SMA) and collagen I, and mRNA expression of monocyte chemotactic protein-1 (MCP-1), transforming growth factor (TGF)-β(1) and TGF-β R-II by RT-PCR 7 days after UUO. RESULTS: In the UUO ATRA and Day 3 ATRA groups, we observed a significant improvement in histological and immunological findings, including macrophage infiltration and improved expression of MCP-1, TGF-β(1), α-SMA and collagen I compared with the UUO Day 7 group. CONCLUSION: ATRA treatment is not only an effective prophylactic strategy, but also a therapeutic strategy for the treatment of progressive renal fibrosis in diseased kidneys.
BACKGROUND:Retinoic acids, a group of natural and synthetic vitamin A derivatives, have potent anti-proliferative, anti-inflammatory and anti-fibrotic properties. We investigated the therapeutic effect of all-trans-retinoic acid (ATRA) on unilateral ureteral obstruction (UUO) model mice. METHODS: First, to evaluate the prophylactic effect, we administered 0.5 mg of ATRA for 3 days before UUO (UUO ATRA). Then, to evaluate the therapeutic effects, we administered 0.5 mg of ATRA 3 days after UUO (Day 3 ATRA). We compared the histological changes and immunostaining of macrophages, α-smooth muscle actin (α-SMA) and collagen I, and mRNA expression of monocyte chemotactic protein-1 (MCP-1), transforming growth factor (TGF)-β(1) and TGF-β R-II by RT-PCR 7 days after UUO. RESULTS: In the UUO ATRA and Day 3 ATRA groups, we observed a significant improvement in histological and immunological findings, including macrophage infiltration and improved expression of MCP-1, TGF-β(1), α-SMA and collagen I compared with the UUO Day 7 group. CONCLUSION:ATRA treatment is not only an effective prophylactic strategy, but also a therapeutic strategy for the treatment of progressive renal fibrosis in diseased kidneys.
Authors: Bhaskar C Das; Pritam Thapa; Radha Karki; Sasmita Das; Sweta Mahapatra; Ting-Chun Liu; Ingrid Torregroza; Darren P Wallace; Suman Kambhampati; Peter Van Veldhuizen; Amit Verma; Swapan K Ray; Todd Evans Journal: Bioorg Med Chem Date: 2013-11-22 Impact factor: 3.641
Authors: Takuto Chiba; Nataliya I Skrypnyk; Lauren Brilli Skvarca; Radostin Penchev; Ke Xin Zhang; Elizabeth R Rochon; Jessica L Fall; Paisit Paueksakon; Haichun Yang; Catherine E Alford; Beth L Roman; Ming-Zhi Zhang; Raymond Harris; Neil A Hukriede; Mark P de Caestecker Journal: J Am Soc Nephrol Date: 2015-06-24 Impact factor: 10.121
Authors: Elaine K Gregory; Antonio Webb; Janet M Vercammen; Megan E Kelly; Banu Akar; Robert van Lith; Edward M Bahnson; Wulin Jiang; Guillermo A Ameer; Melina R Kibbe Journal: J Control Release Date: 2018-01-31 Impact factor: 9.776
Authors: Brian Becknell; Ashley R Carpenter; Jordan L Allen; Michael E Wilhide; Susan E Ingraham; David S Hains; Kirk M McHugh Journal: PLoS One Date: 2013-09-04 Impact factor: 3.240